Nephrol Ther. 2011 Sep;7 Suppl 2:S43-214. doi: 10.1016/S1769-7255(11)70009-8.
In 2009, 8,560 patients with end-stage renal disease living in 20 regions (Alsace, Auvergne, Bourgogne, Bretagne, Centre, Champagne-Ardenne, Corse, Haute-Normandie, Ile de France, la Réunion, Languedoc-Roussillon, Limousin, Lorraine, Midi- Pyrénées, Nord-Pas de Calais, Pays de Loire, Picardie, Poitou- Charentes, Provence-Alpes Côte d'Azur and Rhône-Alpes) covering 57 million inhabitants (89% of the French population), started renal replacement therapy (dialysis or preemptive graft): median age was 70,2 years ; 3,4% had a preemptive graft. The overall crude annual incidence rate of renal replacement therapy for end-stage renal disease was 150 per million population (pmp), with significant differences in sex and age-adjusted incidence across regions (99 to 389 pmh). At initiation, more than one patient out of two had at least one cardiovascular disease and 41% diabetes (92% Type 2 non-insulin-dependent diabetes). On December 31, 2009, 33,558 patients living in the above 20 regions were on dialysis : median age was 70,5 years. On December 31, 2009, 29,181 patients were living with a functioning graft : median age was 54,8 years. In these 20 regions, the overall prevalence of dialysis was 588 pmp, that of renal graft, 510 pmp and the overall rate of renal replacement therapy for end stage renal disease, 1,098 pmp with significant differences in age-adjusted prevalence across regions (809 to 2,709 pmh). In the 2002-2009 cohort of 43,433 incident patients, the overall one-year survival rate was 83%, 45% at 6 years. Survival decreased with age, but remained above 50% at 2 years in patients older than 75 at RRT initiation. Among the 8,688 new patients starting dialysis in 2009 in 23 regions (the 20 regions mentioned above, plus Aquitaine, Pays de Loire and Guadeloupe), 5% had a BMI lower than 18,5 kg/m² and 20% a BMI higher than 30. At initiation, 66% had a haemoglobin value lower than 11 g/l and 10% an albumin value lower than 25 g/l. The first haemodialysis was started in emergency in 33 % of the patients and with a catheter in 54 %. On December 31, 2009, 7 % treated in the dialysis units of the 22 regions (the 20 regions mentioned above, plus Aquitaine and Pays de Loire) received peritoneal dialysis, of which 40% were treated with automated peritoneal dialysis. 95% of the patients on haemodialysis had 3 sessions per week, with a median duration of 4 hours. In the 2002-2009 cohort of incident patients in 18 regions under 60 years, the probability to be at least once on the waiting list for a renal graft is 50% at 15,6 months. In 2009, 2,750 patients received a renal graft. On December 31, 2009, 7,272 patients were on the waiting list for a renal graft in the transplantation centres of the 22 regions. The analysis of the flows between treatments indicates that the proportion of the transplanted patients among RTT patients is increasing. The main source for transplantation is the outcenter patients.
2009年,居住在20个地区(阿尔萨斯、奥弗涅、勃艮第、布列塔尼、中央大区、香槟-阿登、科西嘉、上诺曼底、法兰西岛、留尼汪、朗格多克-鲁西永、利穆赞、洛林、南部-比利牛斯、北部-加来海峡、卢瓦尔河地区、皮卡第、普瓦图-夏朗德、普罗旺斯-阿尔卑斯-蓝色海岸和罗纳-阿尔卑斯)的8560例终末期肾病患者开始接受肾脏替代治疗(透析或择期移植),这些地区覆盖5700万居民(占法国人口的89%):中位年龄为70.2岁;3.4%接受了择期移植。终末期肾病肾脏替代治疗的总体粗年发病率为每百万人口150例(pmp),各地区经性别和年龄调整后的发病率存在显著差异(99至389例/百万人口)。开始治疗时,超过半数的患者至少患有一种心血管疾病,41%患有糖尿病(92%为2型非胰岛素依赖型糖尿病)。2009年12月31日,居住在上述20个地区的33558例患者正在接受透析:中位年龄为70.5岁。2009年12月31日,29181例患者接受了有功能的移植肾:中位年龄为54.8岁。在这20个地区,透析的总体患病率为588例/百万人口,肾移植的患病率为510例/百万人口,终末期肾病肾脏替代治疗的总体患病率为1098例/百万人口,各地区经年龄调整后的患病率存在显著差异(809至2709例/百万人口)。在2002 - 2009年队列中的43433例新发病患者中,总体1年生存率为83%,6年生存率为45%。生存率随年龄下降,但在开始肾脏替代治疗时年龄超过75岁的患者中,2年生存率仍高于50%。在2009年于23个地区(上述20个地区,加上阿基坦、卢瓦尔河地区和瓜德罗普)开始透析的8688例新患者中,5%的患者体重指数(BMI)低于18.5 kg/m²,20%的患者BMI高于30。开始治疗时,66%的患者血红蛋白值低于11 g/l,10%的患者白蛋白值低于25 g/l。33%的患者首次血液透析是在紧急情况下开始的,54%的患者使用了导管。2009年12月31日,在22个地区(上述20个地区,加上阿基坦和卢瓦尔河地区)的透析单位接受治疗的患者中,7%接受腹膜透析,其中40%接受自动腹膜透析。95%的血液透析患者每周进行3次治疗,中位治疗时长为4小时。在18个地区60岁以下的2002 - 2009年新发病患者队列中,在15.6个月时至少有一次进入肾移植等待名单的概率为50%。2009年,2750例患者接受了肾移植。2009年12月31日,在22个地区的移植中心,有7272例患者在等待肾移植。对治疗流程的分析表明,接受移植的患者在肾脏替代治疗患者中的比例正在增加。移植的主要来源是外地患者。